Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases

Yu Tai, Qingtong Wang, Heinrich Korner, Lingling Zhang, Wei Wei

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.

Original languageEnglish (US)
Article number642
JournalFrontiers in Pharmacology
Volume9
Issue numberJUN
DOIs
StatePublished - Jun 26 2018
Externally publishedYes

Fingerprint

Dendritic Cells
Autoimmune Diseases
T-Lymphocytes
Immunological Synapses
Biological Factors
CD58 Antigens
Monoclonal Antibodies
Lymphocyte Function-Associated Antigen-1
Antigen Presentation
Intercellular Adhesion Molecule-1
Type 1 Diabetes Mellitus
Inflammatory Bowel Diseases
Psoriasis
Systemic Lupus Erythematosus
Multiple Sclerosis
Rheumatoid Arthritis
Safety
Proteins

Keywords

  • Activation
  • Autoimmune diseases
  • Biological agents
  • Dendritic cells
  • Immunological synapse
  • T cell

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. / Tai, Yu; Wang, Qingtong; Korner, Heinrich; Zhang, Lingling; Wei, Wei.

In: Frontiers in Pharmacology, Vol. 9, No. JUN, 642, 26.06.2018.

Research output: Contribution to journalReview article

Tai, Yu ; Wang, Qingtong ; Korner, Heinrich ; Zhang, Lingling ; Wei, Wei. / Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases. In: Frontiers in Pharmacology. 2018 ; Vol. 9, No. JUN.
@article{73949349fb1240d987726d283fc19e65,
title = "Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases",
abstract = "The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.",
keywords = "Activation, Autoimmune diseases, Biological agents, Dendritic cells, Immunological synapse, T cell",
author = "Yu Tai and Qingtong Wang and Heinrich Korner and Lingling Zhang and Wei Wei",
year = "2018",
month = "6",
day = "26",
doi = "10.3389/fphar.2018.00642",
language = "English (US)",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Molecular mechanisms of T cells activation by dendritic cells in autoimmune diseases

AU - Tai, Yu

AU - Wang, Qingtong

AU - Korner, Heinrich

AU - Zhang, Lingling

AU - Wei, Wei

PY - 2018/6/26

Y1 - 2018/6/26

N2 - The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.

AB - The interaction between T cell and dendritic cells (DCs) that leads to T cell activation affects the progression of the immune response including autoimmune diseases. Antigen presentation on immune cell surface, formation of an immunological synapse (IS), and specific identification of complex by T cells including two activating signals are necessary steps that lead to T cell activation. The formation of stimulatory IS involves the inclusion of costimulatory molecules, such as ICAM-1/LFA-1 and CD28/B7-1, and so on. Some fusion proteins and monoclonal antibodies targeting costimulatory molecules have been developed and approved to treat autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel disease (IBD), and psoriasis. These biological agents, including CTLA-4-and LFA-3-Ig, anti-CD3 monoclonal antibody, could prevent the successful engagement of DCs by T cell with significant efficacy and safety profile. In this article, we reviewed the molecular mechanisms of T cell activation during the interaction between T cells and DCs, and summarized some biological agents that target costimulatory molecules involved in the regulation of T cell activation.

KW - Activation

KW - Autoimmune diseases

KW - Biological agents

KW - Dendritic cells

KW - Immunological synapse

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85049065128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049065128&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00642

DO - 10.3389/fphar.2018.00642

M3 - Review article

AN - SCOPUS:85049065128

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUN

M1 - 642

ER -